DUBLIN, December 4 /PRNewswire/ -- Azur Pharma Limited ("Azur") today announced that it has entered into a definitive agreement with BioSante Pharmaceuticals, Inc ("BioSante")(Nasdaq: BPAX) to acquire U.S. rights to Elestrin(TM). Elestrin is a fast drying gel formulation of estradiol which is indicated for the treatment of moderate to severe vasomotor symptoms associated with menopause. Elestrin was approved by the U.S. Food and Drug Administration ("FDA") in December 2006 and is patented through June 2022.
Under the terms of the agreement, Azur paid BioSante US$3.3 million comprised of a product licensing fee and payment for the transfer of the trademark and inventories, amongst other items. In addition, Azur Pharma will pay BioSante royalties and contingent milestones based on future net sales of Elestrin.
Azur will market Elestrin to estrogen prescribing physicians in the U.S., comprised mostly of gynecologists, through its women's health and urology sales force. Mr. Seamus Mulligan, Chairman and CEO of Azur, commented, "We are impressed with the potential for Elestrin in the United States given its approved ultra-low dose regimen. The product is an important addition to our women's health product portfolio and we look forward to launching our Elestrin efforts in early 2009."
"We are excited to sign this agreement with Azur," said Mr. Stephen M.
Simes, President and CEO of BioSante. "We believe Azur has excellent,
established relationships with the leading U.S. gynecological practitioners
who write the majority of estrogen prescriptions. Azur is in an excellent
position to capture an important share of the U.S. estrogen therapy market,
which is currently estimated at approximately US$1.4 billion in annual sales,
of which the transdermal segment, mostly patches, is about US$260 million. We
|SOURCE Azur Pharma Limited|
Copyright©2008 PR Newswire.
All rights reserved